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Objectives
To assess the prevalence and risk factors for HBV and HCV coinfection in the Australia HIV
Observational Database (AHOD), and examine outcomes of HIV disease following initiation of highly
active antiretroviral therapy (HAART).
Methods
Analyses were based on 2086 participants recruited to AHOD by September 2002. Of these, 1605
(77%) had been tested for HBV surface antigen, 1704 (82%) for anti-HCV antibody and 1453 (70%)
for both. Demographic and clinical predictors of HBV and HCV coinfection were examined. The
impact of HBV and HCV coinfection on HIV disease progression was assessed by Kaplan-Meier
survival curves and Cox proportional hazard model of time to AIDS events and death.
Results
Among those tested, prevalence of HBV surface antigen and HCV antibody were 6.3% and 13.1%,
respectively (4.8% and 10.7%, respectively, among the entire cohort). In multivariate analyses, the
only independent risk factor for HIV/HBV coinfection was coinfection with HCV. Independent risk
factors for HIV/HCV coinfection were HIV exposure category (with people who reported injecting
drug use [MSM & IDU, IDU only] or receipt of blood or blood products at markedly increased risk)
and HBV coinfection. HIV disease outcomes following first initiation of a HAART regimen were
similar for HIV/HBV and HIV/HCV coinfected patients compared with HIV-only patients in terms of
AIDS-free survival and detectable HIV virus during the first 12 months. However, patients coinfected
with HIV/HCV appeared to have a poorer response to HAART in terms of CD4 count changes, with a
CD4 count increase of 32 cells/mL (95% CI 1–67) less than HIV-only patients.
Conclusions
Coinfection with HBV or HCV is relatively common among HIV-infected participants in AHOD. HIV
disease outcomes following HAART do not appear to be adversely affected by HBV/HCV coinfection,
except for slightly poorer CD4 count responses in HIV/HCV coinfected patients.
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Introduction
Hepatitis B and C viral infections are highly prevalent
among HIV-infected persons, generally as a result of shared
transmission routes [1]. Improved survival due to the
success of highly active antiretroviral therapy (HAART) has
enabled conditions with long latency, such as chronic viral
hepatitis, to become a major source of comorbidity in HIV-
infected populations [2]. HIV modifies the natural history
of hepatitis B virus (HBV), with higher rates of chronic HBV
infection, replicative disease, and progression to advanced
liver disease among persons with HIV/HBV coinfection [2].
The impact of HBVon HIV natural history is less certain [1, 3].
HIV also modifies the natural history of hepatitis C virus
(HCV) infection, with clear evidence of higher HCV viral
load and accelerated liver disease progression in persons
with HIV/HCV coinfection [4]. As with HBV, there is
contradictory evidence on the effects of HCV on HIV
disease progression [5]. Several studies before the era of
HAART showed no impact of HCV on HIV disease
progression [6, 7], while others suggested accelerated HIV
disease progression [8, 9]. A recent longitudinal cohort
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study demonstrated inhibited CD4 cell recovery following
commencement of HAART in persons with HIV/HCV
coinfection [10], but evidence is limited on clinical
progression.
Further longitudinal studies are, therefore, required to
assess the impact of HBV and HCV on HIV disease
progression in the era of HAART. The Australian HIV
Observational Database (AHOD) is a longitudinal study that
has been collecting information (including hepatitis status)
on a cohort of HIV-infected patients since September 1999
[11]. This analysis aimed to assess the seroprevalence of
HBV and HCV within the AHOD population, to identify
characteristics associated with coinfection with chronic
viral hepatitis, and investigate the effect of coinfection on
immunological, virological and clinical progression of HIV
infection.
Methods
Patients and data variables
The AHOD collects data from 26 sites, including hospitals,
sexual health clinics and general practitioners from around
Australia. Data are transferred electronically to the National
Centre in HIV Epidemiology and Clinical Research
(NCHECR), and updated every 6 months. Core data variables
collected on patients include sex, date of birth, date of most
recent visit, HIV exposure category, HBV status, HCV status,
CD4 and CD8 T lymphocyte counts, HIV viral load counts,
antiretroviral and opportunistic infection prophylaxis treat-
ments, AIDS defining illnesses, and date of death.
Risk factors of HBV and HCV coinfection
HBV infection was defined by a positive HBV surface
antigen (HBsAg), and HCV infection by a positive anti-HCV
antibody. Prevalence of HBV infection, HCV infection and
HBV/HCV coinfection was calculated for those with
recorded test results for HBsAg and anti-HCV antibody.
Due to possible testing bias, further prevalence estimates
were calculated for the entire population with the
assumption that all untested patients were negative. Risk
factors for coinfection with HBV and HCV were determined
in cross-sectional analyses using logistic regression mod-
els. If a patient’s HBV or HCV test was prior to entry to the
cohort, or if the test date was missing, analyses were based
on date at cohort entry. If the test date was after entry to
the cohort, analyses were based on the data at this test date.
Univariate analyses were initially performed on each
covariate. The nominal covariates were tested for sig-
nificance using w2 tests for heterogeneity and the ordinal
covariates were tested for significance using tests for trend.
All tests were performed at the 5% significance level.
Missing values of the nominal covariates were dropped for
the tests of trend, but retained when calculating and
reporting the odds ratios. Multivariate logistic models were
used to test the predictors after adjusting for the other
covariates. The models were built using forward step-wise
methods based on the significance tests described above.
Outcomes of HBV/HCV coinfected patients following
HAART
The three endpoints used to test the clinical, virological and
immunological progression of coinfected patients were
time to AIDS or death, detectable viral load at 12 months
and time-weighted CD4 cell counts to 24 months. For the
analyses, only patients who had received HAART and had
recorded test results for both HBV and HCV were included.
The patients were grouped by no hepatitis infection,
infection with HBV only, HCV only and coinfection with
HBV and HCV. Baseline was defined as the date the patient
commenced HAART. No distinction was made between
patients being tested for hepatitis before or after baseline.
The impact of hepatitis coinfection on the clinical
progression of HIV was assessed with Kaplan-Meier
survival curves and a Cox proportional hazard model of
the time to first AIDS defining illness or death. Patients
who did not progress to the endpoint were censored at the
date of the last recorded visit. The effect of hepatitis
coinfection on viraemia at 12 months after baseline was
assessed by logistic regression among patients with base-
line viral load measurement. The effect of hepatitis
coinfection on immunological progression was assessed
by fitting a linear model on time-weighted average
changes in CD4 counts from baseline to 24 months. In
addition to having received HAART, patients were required
to have a baseline CD4 count and at least one follow-up
CD4 count to be included in the analysis.
Covariates tested for inclusion in all multivariate models
were age group, sex, HIV exposure category, viral load at
baseline, CD4 cell count at baseline and antiretroviral
therapy immediately prior to baseline. Each covariate was
tested at the 5% level using the chi-squared test for
heterogeneity if it was a nominal variable or a t-test for
trend if it was ordinal.
Results
Prevalence and risk factors of HBV/HIV and HCV/HIV
coinfection
Of the 2086 AHOD participants, 1605 (77%) had a HBsAg
result, 1704 (82%) had a anti-HCV antibody result, and
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1453 (70%) had results for both tests. One hundred and one
patients tested positive for HBsAg, a HBV prevalence of
6.3% for those with a test result and 4.8% for the entire
cohort. Two hundred and twenty-three patients tested
positive for anti-HCV antibody, a HCV prevalence of 13.1%
for those with a test result and 10.1% for the entire cohort.
Thirty-eight patients tested positive for HBsAg and anti-
HCV antibody, a HBV/HCV coinfection prevalence of 2.6%
for those with a recorded result for both tests and 1.8% for
the entire cohort.
HCV-RNA results were reported for 218 patients who also
had a HCV antibody result. Of HCV antibody positive patients
with HCV-RNA results (n5107), 88 (82%) were HCV-RNA
positive. Of HCV antibody negative patients with HCV-RNA
results (n5111), 5 (4.5%) were HCV-RNA positive.
Risk factors of HBV and HCV coinfection
In univariate analysis, risk factors for HBV coinfection
were HIV exposure through transfusion of blood products,
and HCV coinfection (Table 1). Following adjustment in
multivariate analysis, only HCV coinfection remained
significant. Prevalence of HBV coinfection was 6.2% for
men who have sex with men (MSM), 8.7% for MSM who
also reported injecting drug use (MSM & IDU), 3.0% for
IDUs, and 9.9% for heterosexuals.
Risk factors for HCV coinfection in univariate analysis
were female sex, HIV exposure categories (MSM & IDU,
IDUs, recipients of blood products), HBV coinfection, CD4
count of less than 200 cells/mL [3], and younger age
(Table 2). Following adjustment in multivariate analysis,
HIV exposure category and HBV coinfection remained
significantly associated with HCV coinfection. Prevalence
of HCV coinfection was similar for MSM & IDU (50%), IDUs
(63.9%), and recipients of blood products (57.1%), and
considerably higher than both MSM (8.7%) and hetero-
sexuals (9.9%).
As HCV coinfection and HBV infection were associated,
the relationship between HCV coinfection and prior HBV
exposure (as measured by HBV core antibody status) was
examined. There was a significant association between
HCV coinfection and prior HBV exposure (OR5 1.74; 95%
CI 1.26–2.39, P5o0.001).
Impact of hepatitis coinfection on disease progression
A total of 1271 (60.9%) AHOD patients commenced
HAART, and 181 progressed to an AIDS event. Time to
Table 1 Factors associated with HBV/HIV coinfection
HBV– HBV1 Univariate Multivariate
n % n % OR 95% CI P P * OR 95% CI P P *
Overall 1504 101
Sex Male 1410 93.75 98 97.02
Female 94 6.25 3 2.97 0.46 (0.14–1.48) 0.191 0.191 0.44 (0.14–1.43) 0.174 0.174
Exposure MSM 1086 72.20 73 72.27
MSM & IDU 84 5.58 8 7.92 1.42 (0.66–3.04) 0.371 1.13 (0.50–2.55) 0.767
IDU 32 2.12 1 0.99 0.46 (0.06–3.45) 0.454 0.32 (0.04–2.50) 0.280
Hetero 128 8.51 8 7.92 0.93 (0.44–1.97) 0.850 0.94 (0.44–2.00) 0.874
Blood 11 0.73 3 2.97 4.06 (1.11–14.86) 0.035 3.13 (0.82–11.93) 0.094
Other & NR 163 10.84 8 7.92 0.73 (0.34–1.54) 0.410 0.234 0.71 (0.33–1.50) 0.365 0.551
Age (years) o30 96 6.38 3 2.97
30–39 563 37.43 47 46.53 2.67 (0.81–8.75) 0.105 2.63 (0.80–8.65) 0.110
401 845 56.18 51 50.49 1.93 (0.59–6.31) 0.276 0.717 1.96 (0.60–6.42) 0.266 0.801
Coinfected No 1230 81.78 72 71.28
with HCV Yes 135 8.97 16 15.84 2.02 (1.14–3.58) 0.015 2.02 (1.14–3.58) 0.015
NR 139 9.24 13 12.37 1.60 (0.86–2.96) 0.136 0.028 1.60 (0.86–2.96) 0.136 0.028
RNA at BL o400 639 42.49 47 46.53
(copies/mL) 400–9999 342 22.74 17 16.83 0.68 (0.38–1.19) 0.178 0.66 (0.37–1.18) 0.162
100001 294 19.55 16 15.84 0.74 (0.41–1.32) 0.312 0.73 (0.41–1.32) 0.303
NR 229 15.22 21 20.79 1.25 (0.73–2.13) 0.420 0.212w 1.20 (0.70–2.06) 0.504 0.208w
CD4 at BL o200 182 12.10 17 16.83
(cells/mL) 200–499 516 34.31 30 29.70 0.62 (0.33–1.15) 0.133 0.62 (0.33–1.16) 0.136
5001 606 40.29 32 31.68 0.56 (0.31–1.04) 0.067 0.58 (0.31–1.07) 0.082
NR 200 13.30 22 21.78 1.18 (0.61–2.29) 0.629 0.101w 1.16 (0.59–2.25) 0.665 0.144w
Previous ADI No 1197 79.58 75 74.25
Yes 307 20.41 26 25.74 1.35 (0.85–2.15) 0.202 0.202 1.38 (0.87–2.20) 0.176 0.176
P-values reported for test of homogeneity in nominal covariates and test for trend in ordinal covariates. wpatients with NR data were not included for testing
trend. MSM, men who have sex with men; IDU, injecting drug user; BL, baseline; ADI, AIDS defining illness; P *, overall P.
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AIDS or death was not associated with hepatitis coinfection
(P5 0.37, logrank test) (Fig. 1). The hazard ratios from the
Cox proportional hazard model for progression to AIDS or
death are presented in Table 3. In univariate analysis,
factors associated with clinical progression were higher
HIV viral load, lower CD4 count, and dual antiretroviral
therapy prior to HAART. In the multivariate model, only
lower CD4 count was associated with increased clinical
progression.
There were 901 AHOD patients who commenced HAART
and had a baseline viral load measurement (Table 4).
Similar to clinical progression, there was no association
between hepatitis coinfection status and virological re-
sponse following HAART (P5 0.92). In multivariate
analysis, factors associated with poorer virological re-
sponse were higher baseline HIV viral load and antire-
troviral therapy prior to HAART.
There were 940 AHOD patients who commenced HAART
and had a baseline CD4 count and at least one follow-up
CD4 count recorded. Baseline CD4 cell count were similar
for the following groups: HIV only (mean: 303 cells/mL; SD:
223), HIV/HBV (mean: 274 cells/mL; SD: 210), HIV/HCV
(mean: 300 cells/mL; SD 236), and HIV/HBV/HCV (mean:
270 cells/mL SD: 181) (P5 0.80). HBV coinfection did not
impact on CD4 count response following HAART, however,
in the multivariate analysis HCV was associated with CD4
count response (Table 5). The time-weighted average
increase in CD4 count following commencement of HAART
was approximately 32 cells/mL [3] less in patients with HCV
coinfection compared to those without hepatitis coinfec-
tion (P5 0.040). In multivariate analysis, factors associated
with a poorer CD4 response following commencement of
HAART were antiretroviral therapy prior to HAART, and
baseline CD4 cell count. Patients coinfected with HCV
continued to have a lower response in time-weighted CD4
count following HAART compared to those without
hepatitis infection, although of borderline significance
(P5 0.061).
Discussion
In a large cohort of Australian HIV-infected patients,
several clinically relevant findings were seen. The mode of
HIV acquisition was predictive HCV coinfection, with
particularly strong associations between parenteral modes
and HCV coinfection. The CD4 response following com-
mencement of HAART was impaired in patients with HCV
coinfection, however, the effect was modest and was not
associated with either impaired virological response or
more rapid clinical progression.
Table 2 Factors associated with HCV/HIV coinfection
HCV– HCV1 Univariate P * OR 95% CI P P *
Overall 1481 223
Sex Male 1402 94.67 203 91.03
Female 79 5.33 20 8.97 1.75 (1.05–2.92) 0.033 0.033 1.41 (0.70–2.84) 0.335 0.335
Exposure MSM 1129 76.23 107 47.98
MSM & IDU 51 3.44 51 22.87 10.55 (6.82–16.31) o0.001 10.45 (6.74–16.20) o0.001
IDU 13 0.88 23 10.31 18.67 (9.19–37.91) o0.001 19.46 (9.56–39.58) o0.001
Hetero 128 8.64 14 6.28 1.15 (0.64–2.07) 0.632 1.14 (0.634–2.06) 0.651
Blood 6 0.40 8 3.59 14.07 (4.79–41.30) o0.001 13.18 (4.44–39.04) o0.001
Other & NR 154 10.39 20 8.97 1.37 (0.83–2.27) 0.223 o0.001 1.36 (0.82–2.27) 0.231 o0.001
Age (years) o30 111 7.49 22 9.86
30–39 560 37.81 109 48.88 0.98 (0.59–0.85) 0.944 1.11 (0.63–1.95) 0.721
401 810 54.69 92 41.25 0.57 (0.34–0.95) 0.031 0.001 0.82 (0.46–1.46) 0.499 0.149
Coinfected No 1198 80.89 178 79.82
with HBV Yes 59 3.98 18 8.07 2.05 (1.18–3.56) 0.010 2.17 (1.19–3.95) 0.011
NR 224 15.12 27 12.11 0.81 (0.53–125) 0.339 0.018 0.89 (0.56–1.42) 0.636 0.030
RNA at BL o400 649 43.82 92 41.26
(copies/mL) 400–9999 320 21.61 49 21.97 1.08 (0.74–1.57) 0.684 1.00 (0.67–1.50) 0.988
100001 294 19.85 44 19.73 1.05 (0.72–1.55) 0.782 0.90 (0.59–1.38) 0.636
NR 218 14.72 38 17.04 1.23 (0.82–1.85) 0.321 0.737w 1.02 (0.65–1.60) 0.923 0.659w
CD4 at BL o200 164 11.07 32 14.35
(cells/mL) 200–499 507 34.23 81 36.32 0.82 (0.52–1.28) 0.379 0.80 (0.49–1.31) 0.379
5001 627 42.23 72 32.28 0.59 (0.37–0.92) 0.021 0.68 (0.42–1.12) 0.130
NR 183 12.36 38 17.04 1.06 (0.63–1.78) 0.813 0.011w 0.94 (0.53–1.66) 0.830 0.602w
Previous ADI No 1187 80.15 178 79.82
Yes 294 19.85 45 20.18 1.02 (0.72–1.45) 0.909 0.909 0.92 (0.63–1.36) 0.688 0.388
P-values reported for test of homogeneity in nominal covariates and test for trend in ordinal covariates. wpatients with NR data were not included for testing
trend. MSM, men who have sex with men; IDU, injecting drug user; BL, baseline; ADI, AIDS defining illness. P *, overall P.
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The prevalence of HBV, HCV and HBV–HCV coinfection
in this cohort is considerably higher than the general
Australian population. Recent Australian population level
estimates for HCV and chronic HBV infection are 1.1% [12]
and 0.5% [13], respectively. The corresponding figures
among HIV-infected patients in the AHOD cohort of 6–14%
for both HCV and chronic HBV infection reflect over-
lapping modes of transmission for these three blood-borne
viruses. The prevalence of HBV coinfection among
Australian HIV-infected patients is similar to several other
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Fig. 1 Time to first AIDS defining illness or death by hepatitis B and C coinfection status.
Table 3 Time to first AIDS defining illness or death
Non-events Events Univariate Multivariate
n % n % HR 95% CI P P * HR 95% CI P P *
Overall 1090 181
Hepatitis Status HBV–/HCV– 889 81.56 147 81.21
HBV1 /HCV– 52 4.77 12 6.62 1.34 (0.74–2.41) 0.330 1.27 (0.71–2.29) 0.423
HBV–/HCV1 130 11.92 22 12.15 1.05 (0.67–1.65) 0.824 0.99 (0.63–1.56) 0.985
HBV1 /HCV1 19 1.74 0 0 – – – 0.810 – – – 0.885
Sex Male 1022 93.76 173 95.58
Female 68 6.24 8 4.42 0.73 (0.36–1.48) 0.382 0.382 0.82 (0.40–1.66 0.576 0.576
Age (years) o30 161 14.77 30 16.57
30–39 460 42.20 74 40.88 0.83 (0.54–1.27) 0.384 0.84 (0.55–1.29) 0.436
401 469 43.03 77 42.54 0.84 (0.55–1.29) 0.429 0.547 0.85 (0.56–1.30) 0.453 0.552
Exposure category MSM 783 71.83 138 76.24
Other 280 25.69 40 22.10 0.91 (0.64–1.29) 0.603 0.88 (0.61–1.25) 0.465
NR 27 2.48 3 1.66 0.70 (0.22–2.21) 0.547 0.743 0.65 (0.21–2.04) 0.458 0.601
RNA at BL o400 188 17.25 16 8.84
(copies/mL) 400–9999 382 35.04 39 21.55 1.09 (0.61–1.94) 0.781 1.02 (0.57–1.84) 0.933
100001 256 23.49 54 29.83 2.00 (1.14–3.50) 0.015 1.49 (0.84–2.64) 0.168
NR 264 24.22 72 39.78 2.14 (1.24–3.70) 0.006 0.003 1.37 (0.71–2.62) 0.345 0.082
CD4 at BL o200 226 20.74 67 37.02
(cells/mL) 200–499 413 37.89 46 25.41 0.43 (0.30–0.63) o0.001 0.43 (0.30–0.63) o0.001
5001 232 21.28 13 7.18 0.24 (0.13–0.44) o0.001 0.24 (0.13–0.44) o0.001
NR 219 20.09 55 30.39 0.84 (0.59–1.20) 0.330 o0.001 0.84 (0.59–1.20) 0.330 o0.001
Previous ART None 666 61.10 77 42.54
Mono 63 5.78 11 6.08 1.26 (0.67–2.28) 0.467 1.11 (0.59–2.10) 0.739
Double 361 33.11 93 51.38 1.64 (1.21–2.22) 0.002 0.006 1.42 (1.04–1.94) 0.026 0.081
P-values reported for test of homogeneity in nominal covariates and test for trend in ordinal covariates. wpatients with NR data were not included for testing
trend. MSM, men who have sex with men; BL, baseline; ART, antiretroviral therapy. P *, overall P.
HIV/HBV, HIV/HCV and HAART 245
r 2003 British HIV Association HIV Medicine (2003) 4, 241–249
Table 4 Detectable viral load at 12 months after baseline
Undetectable Detectable Univariate Multivariate
n % n % OR 95% CI P P * OR 95% CI P P *
Overall 431 470
Hepatitis status HBV–/HCV– 352 81.67 399 80.93
HBV1 /HCV– 21 4.87 27 5.48 1.13 (0.63–2.04) 0.675 1.04 (0.54–2.01) 0.903
HBV–/HCV1 51 11.83 61 12.37 1.05 (0.71–1.57) 0.792 1.16 (0.74–1.81) 0.520
HBV1 /HCV1 7 1.62 6 1.22 0.76 (0.25–2.27) 0.618 0.919 0.91 (0.26–3.17) 0.878 0.929
Sex Male 397 92.11 470 95.33
Female 34 7.89 23 43.67 0.57 (0.33–0.99) 0.044 0.044 0.70 (0.36–1.34) 0.279 0.279
Age (years) o30 62 14.39 72 14.60
30–39 180 41.76 214 43.41 1.02 (0.69–1.52) 0.907 0.96 (0.62–1.46) 0.845
401 189 43.85 207 41.99 0.94 (0.64–1.40) 0.770 0.653 0.85 (0.55–1.31) 0.470 0.392
Exposure category MSM 292 67.75 368 74.65
Other 139 32.25 125 26.60 0.71 (0.54–0.95) 0.021 0.21 0.72 (0.53–0.99) 0.042 0.042
RNA at baseline o400 144 33.41 36 7.30
(replicates/mL) 400–9999 152 35.27 225 45.64 5.92 (3.89–9.00) o0.001 6.80 (4.39–10.53) o0.001
100001 109 25.29 153 31.03 5.61 (3.61–8.72) o0.001 6.33 (4.01–9.99) o0.001
NR 26 6.03 79 16.02 12.15 (6.84–21.58) o0.001 o0.001 13.91 (7.68–25.20) o0.001 o0.001
CD4 at baseline o200 89 20.65 126 25.56
(cells/mL) 200–499 201 46.64 183 37.12 0.64 (0.46–0.90) 0.010 0.75 (0.51–1.09) 0.133
5001 113 26.22 112 22.72 0.70 (0.48–1.02) 0.064 1.11 (0.72–1.72) 0.617
NR 28 6.50 72 14.60 1.82 (1.09–3.04) 0.023 0.069 1.12 (0.50–2.54) 0.777 0.527
Previous ART None 309 71.69 261 52.94
Mono 20 4.64 21 4.26 1.24 (0.66–2.34) 0.501 1.53 (0.76–3.08) 0.235
Double 102 23.67 211 42.80 2.45 (1.83–3.27) o0.001 o0.001 2.81 (2.05–3.89) o0.001 o0.001
P-values reported for Wald’s Chi-squared test of homogeneity in nominal covariates and t-test for trend in ordinal covariates. wpatients with NR data were not
included for testing trend. MSM, men who have sex with men; BL, baseline; ART, antiretroviral therapy. P *, overall P.
Table 5 Time weighted average change in CD4 counts from baseline
Average time-weighted Univariate Multivariate change in CD4 count
n Mean St. Dev. D** 95% CI P P * D 95% CI P P *
Overall 940 180.72 173.58
Hepatitis HBV–/HCV– 772 185.20 174.86
Status HBV1 /HCV– 48 171.22 148.05  13.98  64.61, 36.66 0.588  12.39  60.85, 36.07 0.616
HBV–/HCV1 108 150.27 177.99  34.93  69.91, 0.04 0.050  32.12  65.70, 1.46 0.061
HBV1 /HCV1 12 204.20 124.51 19.00  80.04, 118.03 0.707 0.241 13.09  81.64, 107.82 0.786 0.287
Sex Male 880 181.28 173.99
Female 60 172.42 168.65  8.86  54.34, 36.61 0.702 0.702  10.26  53.84, 33.32 0.644 0.644
Age o30 142 169.69 175.34
(years) 30–39 396 202.80 176.82 33.11  0.05, 66.26 0.050 38.04 6.21, 69.87 0.019
401 402 162.85 167.64  6.84  39.93, 26.25 0.685 0.137 5.54  26.30, 37.37 0.733 0.484
Exposure MSM 683 181.48 177.63
Category Other & NR 257 178.69 162.66  2.79  27.73, 22.15 0.826 0.826  12.74  36.73, 11.26 0.298 0.298
Viral load o400 181 164.69 180.32
at baseline 400–9999 383 193.20 175.31 28.51  2.13, 59.16 0.068 11.09  18.56, 40.73 0.463
100001 281 185.94 154.05 21.25  11.13, 53.64 0.198 7.50  23.98, 38.99 0.640
NR 95 145.45 154.05  19.24  62.29, 23.81 0.381 0.286  23.78  66.52, 18.96 0.275 0.464
CD4 o200 339 192.85 15.19
at baseline 200–499 449 199.46 161.23 6.61  17.38, 30.61 0.589  0.31  23.81, 23.20 0.980
(cells/mL) 5001 152 98.28 225.53  94.57  127.12,  62.02 o0.001 o0.001  103.54  135.44,  71.64 o0.001 o0.001
Previous None 547 210.99 181.51
ART Mono 50 129.37 165.88  81.62  130.92,  32.32 o0.001  81.36  129.48,  33.24 0.001
Double 343 139.927 150.55  71.06  94.04,  48.08 o0.001 o0.001  75.55  98.09,  53.02 o0.001 o0.001
P-values reported for Wald’s Chi-squared test of homogeneity in nominal covariates and t-test for trend in ordinal covariates. wpatients with NR data were not
included for testing trend. **Mean differences in time-weighted change in CD4 cell count. MSM, men who have sex with men; BL, baseline; ART, antiretroviral
therapy. P *, overall P.
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industrialized countries [14]. In contrast, the prevalence of
HCV coinfection is lower than the 20–30% seen in
countries such as the USA, Spain and Italy [15–17], where
injecting drug use contributes a larger proportion of HIV
infection than in Australia [18].
Independent predictors for HBV and HCV coinfection
were found within AHOD. An association between HBV
infection and HCV infection indicates shared transmission
routes, in particular parenteral exposure [19]. Approxi-
mately 12% of people diagnosed with HIV in Australia
have reported either injecting drug use or receipt of blood
products, including 4% who reported both injecting drug
use and homosexual contact [18]. The major determinant
of HCV coinfection in AHOD was route of HIV transmis-
sion, with more than half of patients who acquired HIV
through parenteral routes found to have HCV coinfection.
In addition, patients who reported both male homosexual
contact and injecting drug use had a HCV coinfection
prevalence of above 50%. The majority of men in this
category may have acquired HIV through sexual contact
and HCV through parenteral exposure, as HIV prevalence
among injecting drug users in Australia has remained at
low levels throughout the HIV epidemic [18]. Approxi-
mately 9% of both heterosexual and male homosexual
patients (with no reported injecting drug use) were reported
to be HCV coinfected. Possible explanations for HCV
infection in these two groups are sexual transmission,
underreporting of injecting drug use, or other parenteral
exposure, such as tattooing or body piercing.
Among AHOD patients commenced on HAART, those
with HCV coinfection had an impaired CD4 count response.
This finding, including the magnitude of the effect, is
consistent with that found in the Swiss Cohort Study [10],
with both studies demonstrating an approximately 40 cells/
mL [3] lower CD4 count increase in the 24 months following
commencement of HAART. Direct HCV pathogenicity on
lymphocytes has been suggested as the mechanism for this
effect, and earlier treatment of HCV coinfection in people
with HIV proposed as a consequence [10]. Delayed CD4
recovery in patients with HCV coinfection is not related to
differences in virological control as shown in our study and
by others [10, 20, 21]. Longer-term follow-up and further
studies are required to examine the impact of delayed CD4
recovery on clinical progression, as two recent studies have
shown no impact [20] and increased progression [21]
among patients with HCV coinfection. In contrast to HCV,
coinfection with HBV does not appear to influence CD4
count recovery following commencement of HAART,
although our study appears to be the first to examine this
issue.
There are several limitations to our study that should be
considered in relation to the findings. First, HBV and HCV
status was based on clinician reporting to the AHOD
database rather than through a standardized serological
survey. Second, HBV and HCV status was not available for
all patients in AHOD. As AHOD includes information on
over 2000 patients, and 77–82% of patients had HBV and
HCV testing, clinically significant associations with coin-
fection should have been detected. Third, HCV coinfection
status was based on antibody rather than HCV RNA
detection, and HBV coinfection status in some cases may
have been based on a single positive HBsAg result.
However, the vast majority in both HBV and HCV
coinfection categories could be expected to have chronic
viral hepatitis. The limited HCV-RNA testing among
patients with a positive HCV antibody result suggested
that 82% had chronic HCV infection. Finally, no assess-
ment of liver disease outcomes was conducted. Although
liver biopsy-based information is not available, cause of
death is being collected in AHOD, therefore, liver disease-
associated mortality will be monitored prospectively.
As survival for patients with HIV infection continues to
improve, therapeutic toxicity and comorbid conditions,
such as chronic viral hepatitis will be major management
issues. Longitudinal monitoring such as that undertaken in
observational cohort studies will be a crucial means of
examining the changing natural history of HIV disease.
Factors such as the impact of hepatitis coinfection on
antiretroviral therapy choice, toxicity, and regimen change
should also be examined in such cohorts.
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